Drugs / ZAPNOMETINIB
ZAPNOMETINIB
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05555823 | Jun 2022 → Jul 2023 | — | Atriva Therapeutics GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04385420 | Apr → Aug 2019 | influenza | Atriva Therapeutics GmbH | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04776044 | Apr 2021 → Jun 2022 | COVID-19 | Atriva Therapeutics GmbH | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZAPNOMETINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL481949 ↗ |
| Known as | ATR-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04776044 ↗ |
| Known as | PD0184264 | “Each subject in the SAD cohorts was to receive a single dose of the MEK inhibitor ATR-002 (PD0184264), with a starting dose of 100 mg ATR-002 or placebo:” NCT04385420 ↗ |
| Action | Inhibit | “MEK inhibitor” NCT04385420 ↗ |
| Modality | Small molecule | — CHEMBL481949 ↗ |
| Route | Oral | “Drug ATR-002 administered as film-coated tablet via oral route” NCT04385420 ↗ |